Rimecor has an antihypoxic effect. Normalizes the energy metabolism of cells that have undergone hypoxia or ischemia. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function.
The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (enhancement of aerobic glycolysis and slowing down of oxidation of fatty acids due to selective inhibition of long chain 3-ketoacyl-CoA-thiolase). Supported by myocardial contractility, prevents intracellular depletion of ATP and creatine phosphate.In conditions of acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis, caused by myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemia zone, reduces the yield creatine phosphokinase from cells and the severity of myocardial ischemic damage.
When angina pectoris reduces the frequency of attacks (decreases the daily requirement for nitrates), after two weeks of treatment, exercise tolerance increases. Limits sharp fluctuations in blood pressure. Reduces dizziness and noise in the ears of ischemic etiology, hearing and vestibular samples improve. In vascular pathology, the eye restores the functional activity of the retina.